CONFIRM研究:纳武利尤单抗治疗复发间皮瘤的双盲安慰剂对照III期临床试验方案
CONFIRM是一项英国随机双盲安慰剂对照III期试验,计划入组336例既往至少接受过二线治疗的胸膜或腹膜间皮瘤患者,按2:1随机接受纳武利尤单抗240 mg单药或生理盐水安慰剂静脉输注最长12个月,主要终点为总生存期,采用意向性治疗原则和Cox回归分析。
要点
- 复发间皮瘤患者随机接受纳武利尤单抗或安慰剂,主要终点为总生存期。
- 纳武利尤单抗剂量为240 mg,30分钟静脉输注,疗程最长12个月。
- 次要终点包括无进展生存期、客观缓解率、毒性、生活质量和成本效益。
核心结论
- 该试验旨在评估纳武利尤单抗能否改善复发间皮瘤患者的总生存期。
- 若证实临床有效、安全且具成本效益,纳武利尤单抗可能成为英国新的标准治疗。
研究设计与样本
- 英国多中心随机双盲安慰剂对照III期临床试验(CONFIRM)。
- 计划入组336例既往至少接受过二线治疗的胸膜或腹膜间皮瘤患者。
- 按2:1随机分配至纳武利尤单抗组或安慰剂组,并按上皮样/非上皮样分层。
关键数值与推荐
- 纳武利尤单抗240 mg单药或生理盐水安慰剂,30分钟静脉输注,最长12个月。
- 主要终点为总生存期,采用意向性治疗原则和Cox回归分析。
- 次要终点包括无进展生存期、客观缓解率、毒性、生活质量和成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mesothelioma is an incurable, apoptosis-resistant cancer caused in most cases by previous exposure to asbestos and is increasing in incidence. It represents a growing health burden but remains under-researched, with limited treatment options. Early promising signals of activity relating to both PD-L1- and PD-1-targeted treatment in mesothelioma implicate a dependency of mesothelioma on this immune checkpoint. There is a need to evaluate checkpoint inhibitors in patients with relapsed mesothelioma where treatment options are limited. METHODS: The addition of 12 months of nivolumab (anti-PD1 antibody) to standard practice will be conducted in the UK using a randomised, placebo-controlled phase III trial (the Cancer Research UK CONFIRM trial). A total of 336 patients with pleural or peritoneal mesothelioma who have received at least two prior lines of therapy will be recruited from UK secondary care sites. Patients will be randomised 2:1 (nivolumab:placebo), stratified according to epithelioid/non-epithelioid, to receive either 240 mg nivolumab monotherapy or saline placebo as a 30-min intravenous infusion. Treatment will be for up to 12 months. We will determine whether the use of nivolumab increases overall survival (the primary efficacy endpoint). Secondary endpoints will include progression-free survival, objective response rate, toxicity, quality of life and cost-effectiveness. Analysis will be performed according to the intention-to-treat principle using a Cox regression analysis for the primary endpoint (and for other time-to-event endpoints). DISCUSSION: The outcome of this trial will provide evidence of the potential benefit of the use of nivolumab in the treatment of relapsed mesothelioma. If found to be clinically effective, safe and cost-effective it is likely to become the new standard of care in the UK. TRIAL REGISTRATION: EudraCT Number: 2016-003111-35 (entered on 21 July 2016); ClinicalTrials.gov, ID: NCT03063450 . Registered on 24 February 2017.
引用
- Fennell DA, Kirkpatrick E, Cozens K, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018. PMID: 29669604. doi:10.1186/s13063-018-2602-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。